HIV, Infectious Diseases
HIV drug could offer yearlong protection with a single shot
A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the pharmacokinetics, safety and tolerability of two intramuscular formations of lenacapavir in participants ages 18-55 without HIV.
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
The axing of some 10,000 programs has consigned untold numbers of children and refugees to death, officials say. Documents ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
A peer reviewer questioned the premise of our study into the potential impact of abruptly ending PEPFAR funding. Then it ...
Clinical Trials Arena on MSN2d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
News Medical on MSN2d
Gaps in HPV cancer screening and prevention identified for people living with HIVA new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...
A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback